In men and gender-diverse persons, twice-yearly subcutaneous lenacapavir vs. daily oral F/TDF reduced HIV incidence.

Zar, Fred Arthur; ACP Journal Club Editorial Team at McMaster University · Ann Intern Med · 2025

Where this comes from

Abstract

GIM/FP/GP: [Formula: see text] Infectious Disease: [Formula: see text] Public Health: [Formula: see text].